Family-owned Medacta International, Inc. recently rolled out the red carpet for its new MasterLoc Hip System and GMK Sphere Knee at the 26th American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting in Dallas, Texas.
Medacta International Showcases MasterLoc Hip, GMK Sphere Knee
2 min read Premium comments
Secondary
“Medacta’s commitment to surgical innovation is on display at this year’s AAHKS Annual Meeting, including our new MasterLoc cementless tapered wedge implant, ” said Francesco Siccardi, company executive vice president, in the November 10, 2016 news release. “The launch of MasterLoc brings Medacta into the proximally coated, flat tapered wedge hip market and allows us to provide yet another option for our surgeon partners considering minimally invasive hip replacement.”
“The MasterLoc Hip System is the newest addition to the company’s cementless implant portfolio. The implant features Medacta’s Mectagrip plasma-sprayed titanium coating, designed to enhance initial fixation due to its high coefficient of friction and the potential long-term stability inherent to titanium plasma-sprayed devices.”
“The MasterLoc cementless tapered wedge implant is the result of 40 years of clinical evolution since initial designs were described in the 1970s. The MasterLoc was designed to be implanted through all minimally invasive, muscle-sparing techniques, including Medacta’s Anterior Minimally Invasive Surgery (AMIS®) technique. It can also be coupled with any of Medacta’s acetabular products, including the recently announced Mpact® Double Mobility Acetabular System.”
“Medacta’s GMK Sphere is an innovative primary total knee system designed to deliver maximum functional stability along with patient-specific kinematics to improve patient satisfaction. In the past five years, more than 20, 000 GMK Sphere Knees have been implanted worldwide.”
“The GMK Sphere has become our most popular knee product, capturing over half of Medacta’s knee business, ” continued Siccardi. “The surgeon and patient feedback we’ve received has been incredibly encouraging and we look forward to even more success ahead.”
Siccardi told OTW, “The MasterLoc Hip System, Medacta’s first cementless tapered wedge implant, adds even more diversity to our hip portfolio. We put a strong emphasis on providing orthopedic surgeons with end-to-end solutions that meet their joint replacement needs, from implants and instruments to education and training, and the MasterLoc allows us to satisfy even more surgeons looking to use the Medacta system.”
“We’re feeling positive about our GMK Sphere Knee implant as well, which recently reached the impressive milestone of 20, 000 implants in the past five years.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.